NASDAQ · UNCY
Healthcare · Biotechnology
$4.22
Down-$0.33 (-7.25%)
Updated Oct 5, 2026, 2:28 AM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · UNCY
1M range · 19 trading sessions · Daily adjusted prices
Prices through Oct 2, 2026
UNCY closed at $4.22 after 19 trading sessions, down 16.10% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 2, 2026 | $4.62 | $4.62 | $4.09 | $4.22 | 1.51M |
| Oct 1, 2026 | $4.71 | $4.76 | $4.545 | $4.55 | 1.07M |
| Sep 30, 2026 | $4.61 | $4.81 | $4.5743 | $4.695 | 862.71K |
| Sep 29, 2026 | $4.66 | $4.70 | $4.28 | $4.55 | 2.31M |
| Sep 28, 2026 | $4.66 | $4.68 | $4.53 | $4.64 | 601.48K |
| Sep 25, 2026 | $4.83 | $4.85 | $4.66 | $4.695 | 495.05K |
| Sep 24, 2026 | $4.81 | $4.855 | $4.62 | $4.81 | 660.31K |
| Sep 23, 2026 | $4.94 | $4.96 | $4.73 | $4.81 | 771.82K |
| Sep 22, 2026 | $4.80 | $4.97 | $4.76 | $4.96 | 588.06K |
| Sep 21, 2026 | $4.85 | $4.85 | $4.7449 | $4.77 | 448.53K |
| Sep 18, 2026 | $4.80 | $4.85 | $4.76 | $4.80 | 1.11M |
| Sep 17, 2026 | $4.86 | $4.88 | $4.71 | $4.77 | 648.26K |
| Sep 16, 2026 | $4.85 | $4.90 | $4.6914 | $4.78 | 906.36K |
| Sep 15, 2026 | $5.15 | $5.15 | $4.71 | $4.71 | 1.69M |
| Sep 14, 2026 | $5.27 | $5.35 | $5.13 | $5.15 | 671K |
| Sep 11, 2026 | $5.34 | $5.40 | $5.22 | $5.29 | 1.12M |
| Sep 10, 2026 | $5.07 | $5.62 | $5.04 | $5.31 | 1.24M |
| Sep 9, 2026 | $5.03 | $5.14 | $5.01 | $5.12 | 906.97K |
| Sep 8, 2026 | $5.13 | $5.2199 | $5.025 | $5.03 | 817.18K |
The latest Smart Investors Daily articles mentioning UNCY.
Company
Market Activity
Research & News
UNCY research
Company profile and research snapshot.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 29, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 20, 2026 | Benchmark | Speculative Buy | — |
| Aug 13, 2026 | Guggenheim | Buy | — |
| Aug 13, 2026 | B. Riley Securities | Buy | — |
| Jul 1, 2026 | Benchmark | Speculative Buy | — |
No generated briefing is available yet.
Benzinga · Sep 29, 2026
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowers the price target from $15 to $13.
Yahoo · Sep 29, 2026
Resubmission of NDA includes Chemistry, Manufacturing, and Controls (CMC) data from a new drug product manufacturing vendor The resubmission package includes 12 months of OLC drug product stability data from the new manufacturing vendor Company anticipates FDA acceptance of the NDA within 30 days of resubmission; new assigned PDUFA date expected to be 6 months from resubmissionCurrent cash position allows runway into 2H 2027 MOUNTAIN VIEW, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Unicycive The
Benzinga · Sep 29, 2026
The Company anticipates United States Food and Drug Administration (FDA) acceptance of the NDA within 30 days and a new assigned PDUFA date to be six months from the date of resubmission.The NDA resubmission includes
Benzinga · Sep 28, 2026
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001766140/000121390026104076/ea0306890-8k_unicycive.htm
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning UNCY.
